A practical reference on glucagon receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-05-13 and is reviewed periodically as new material appears.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Identification and purity assessment typically rely on reversed-phase high-performance liquid chromatography, often paired with mass spectrometry. Mass measurement confirms the expected molecular mass and can reveal truncations or modifications. Peptide mapping and sequencing techniques provide sequence-level confirmation when needed. Because related peptide impurities can behave similarly in a single method, orthogonal techniques are usually combined. Reported purity values depend heavily on the method used and should be interpreted with that in mind.
Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide of about 39 residues | Backbone derived from a GIP sequence |
| Molecular mass | Approximately 4.7 kDa | Peptide chain plus fatty diacid moiety |
| Receptor targets | GLP-1, GIP, glucagon | Unimolecular triple agonist |
| Typical storage temperature | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
| Common analytical method | LC-MS/MS | Used for plasma quantification and purity checks |
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
Solid material is generally held at -20 °C or colder, while reconstituted solutions are kept at 2-8 °C and used within a short window. Buffers that maintain a slightly acidic to neutral pH tend to improve short-term peptide stability. Repeated warming and cooling of stock solutions promotes aggregation and should be avoided. Container closures should remain intact, since adsorption to some plastics can reduce the amount of peptide in solution.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
This new recommendation provides a five-week window For valid culture results that include births that occur up to a gestational age of at least 41 weeks. The culture-based screening approach is followed in most developed countries such as the United States, France, Spain, Belgium, Canada, Argentina, and Australia. . The risk-based strategy is followed in the United Kingdom, and the Netherlands.
Dekaranger, Ban acquires a variant of the SP License called the Fire Squad License (ファイヤースクワッドライセンス, Faiyā Sukuwaddo Raisensu), which allows him to transform Murphy K-9 into his armor to assume Battlizer Mode (バトライザーモード, Batoriza Mōdo) where he gains a rocket booster pack and a pair of siren lasers. In this form, he wields a sword/rifle hybrid, which allows him to perform the Battlize Fire Drive (バトライズファイヤードライブ, Batoraizu Faiyā Doraibu) finisher. As of the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After, Ban has acquired a red-colored S.W.A.T. Mode vest to signify his membership in the Fire Squad. During the events of the direct-to-video anniversary special Tokusou Sentai Dekaranger 20th: Fireball Booster, he acquires a variant of the SP License called the SP1 License (SP1ライセンス, Esu Pī Wan Raisensu), which allows him to transform into the armored Premiere Deka Red (プレミアデカレッド, Puremia Deka Reddo). While transformed, he wields the D-Sword Vega, which allows him to perform the Boost Slash (ブーストスラッシュ, Būsuto Surasshu) finisher. Ban is portrayed by Ryuji Sainei (載寧 龍二, Sainei Ryūji).
GoodRx Holdings, Inc. is an American healthcare company that operates a telemedicine platform and free-to-use website and mobile app that track prescription drug prices in the United States and provide drug coupons for discounts on medications. GoodRx compares prescription drug prices at more than 75,000 pharmacies in the United States. The platform allows users to consult a doctor online and obtain a prescription for certain types of medications.
Zinc is an essential element for all known forms of life. In humans, zinc is required for the function of over 300 enzymes and 1000 transcription factors, and is stored and transferred in metallothioneins. It is the second most abundant trace metal in humans after iron. It is the only metal which appears in all enzyme classes. In proteins, zinc ions are often coordinated to the amino acid side chains of aspartic acid, glutamic acid, cysteine and histidine. The theoretical and computational description of this zinc binding in proteins (as well as that of other transition metals) is difficult. Roughly 2–4 grams of zinc are distributed throughout the human body. Most zinc is in the brain, muscle, bones, kidney, and liver, with the highest concentrations in the prostate and parts of the eye. Semen contains a particularly high amount of zinc, a key factor in prostate gland function and reproductive organ growth. Zinc homeostasis of the body is mainly controlled by the intestine. Here, ZIP4 and especially TRPM7 were linked to intestinal zinc uptake essential for postnatal survival. In humans, the biological roles of zinc are ubiquitous. It interacts with "a wide range of organic ligands", and has roles in the metabolism of RNA and DNA, signal transduction, and gene expression. It also regulates apoptosis. A review from 2015 indicated that about 10% of human proteins (~3000) bind zinc, in addition to hundreds more that transport and traffic zinc; a similar in silico study in the plant Arabidopsis thaliana found 2367 zinc-related proteins.
Sources: en.wikipedia.org
Although some medical authorities recommend mirroring the terminology transgender people use to describe their own genitals, such usage may feel uncomfortable and intimate to some transgender people, who prefer to use different terms in medical contexts than they would in personal settings. At the same time, patients may also be uncomfortable with anatomical terms they perceive as gendered. Specialists recommend being open to using sex-neutral terms for organs, such as external genitals or lateral folds for the labia, internal reproductive organs for the uterus and ovaries, and chest for the breasts. Style guides such as the Publication Manual of the American Psychological Association and AMA Manual of Style recommend using gender-neutral language and distinguishing between gender and biological sex, but do not give guidance on specific anatomical terminology.
== Contamination sources and removal == Bacteria, particles, organic carbon, ions, and dissolved gases are all present in typical municipal water systems and must be removed to create ultrapure water.
It was, unlike the first film, a true representation of Judge Dredd ... Karl Urban was a fine Dredd and I'd be more than happy to see him in the follow-up. Olivia Thirlby excelled as Anderson ... The character and storyline are pure Dredd." Dredd has been recognised as a cult film since its release. Some reviewers drew comparisons between Dredd and The Raid: Redemption, another action film released a few months earlier, noting that similar elements in setting, story, and characters made Dredd appear derivative. However, Garland and Urban explained that the timing of when the films were shot would have made plagiarism impossible.
=== Droplet transportation === Discrete droplets can be transported in a highly controlled way using an array of electrodes. In the same way droplets move from an uncharged electrode to a charged electrode, or vice versa, droplets can be continuously transported along the electrodes by sequentially energizing the electrodes. Since droplet transportation involves an array of electrodes, multiple electrodes can be programmed to selectively apply a voltage to each electrode for a better control over transporting multiple droplets.
), i.e. a nonlinear set of differential equations with periodically varying parameters. It is well known that this class of dynamical systems may undergo very interesting and complex phenomena of nonlinear parametric resonance. It is easy to see that if:
Sources: en.wikipedia.org
As of the mid-2020s retatrutide remains investigational and is not an approved medicine in the United States or the European Union. It has been supplied mainly to participants in clinical trials. Labels and availability can change, so regulatory listings should be checked directly.
Dual agonists act at the GLP-1 and GIP receptors, whereas retatrutide adds glucagon receptor activity on the same peptide. This third activity is the main structural and pharmacological distinction discussed in the literature. Direct head-to-head comparisons remain limited.
Reports usually give the study code LY3437943 alongside the name, the dose in milligrams, and the week at which an endpoint was measured. Percent body-weight change is the most frequent headline measure. Units and populations vary, so comparisons across reports require care.
Mass spectrometry provides a mass value that can be compared with the expected value, while peptide mapping examines fragmentation patterns. Together these techniques support identity claims better than a single measurement can.